Open Access<p>Comparison of Real-World Treatment Patterns Among Psoriasis Patients Treated with Ixekizumab or Adalimumab</p>
Author(s) -
Andrew Blauvelt,
Nianwen Shi,
Russel Burge,
William N Malatestinic,
Chen-Yen Lin,
Carolyn R. Lew,
Nicole M. Zimmerman,
Orin Goldblum,
Baojin Zhu,
Mwangi J Murage
Publication year - 2020
Publication title -
patient preference and adherence
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.885
H-Index - 48
ISSN - 1177-889X
DOI - 10.2147/ppa.s233993
Subject(s) - medicine , adalimumab , ixekizumab , odds ratio , discontinuation , hazard ratio , confidence interval , psoriasis , cohort , psoriatic arthritis , dermatology , disease , secukinumab
There is lack of real-world treatment pattern comparison data between ixekizumab and adalimumab which are approved for the treatment of moderate-to-severe plaque psoriasis.